APA (7th ed.) Citation

R, H., J, M., J, S., L, P., A, J., JG, B., . . . V, M. (2021). Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma. Future oncology (London, England), 17(19), 2499. https://doi.org/10.2217/fon-2020-1225

Chicago Style (17th ed.) Citation

R, Hájek, et al. "Ixazomib-lenalidomide-dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma." Future Oncology (London, England) 17, no. 19 (2021): 2499. https://doi.org/10.2217/fon-2020-1225.

MLA (9th ed.) Citation

R, Hájek, et al. "Ixazomib-lenalidomide-dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma." Future Oncology (London, England), vol. 17, no. 19, 2021, p. 2499, https://doi.org/10.2217/fon-2020-1225.